

PRESS RELEASE

AVITHRAPID Launches 'AVITHRAPID SEMINARS' to Advance Pandemic Preparedness and Antiviral Research

Bringing Together Regulators, Pharma, and Scientific Leaders to Shape the Future of Antiviral Strategies

Lugano, 3 March 2025 – AVITHRAPID, the cutting-edge European initiative dedicated to accelerating antiviral research and pandemic preparedness, is proud to announce the launch of AVITHRAPID SEMINARS—a dynamic series of expert-driven discussions uniting regulatory authorities, pharmaceutical industry leaders, European projects, and key stakeholders.

A Platform for Innovation and Collaboration


The **AVITHRAPID SEMINARS** aim to foster strategic dialogue on antiviral innovation, therapeutic development, and public health security. These sessions will serve as a bridge between science, policy, and industry, ensuring that the latest advancements in antiviral research translate into impactful policies and real-world applications.

The first closed-door seminar is scheduled for Monday, March 3, 2025, featuring a high-level discussion with HERA (DG SANTE), focusing on pandemic preparedness and antiviral strategies.

Two public sessions will follow in Summer and Autumn 2025, welcoming industry experts, policymakers, and researchers to exchange insights and shape the future of antiviral preparedness.



Join the Conversation

AVITHRAPID invites pharmaceutical companies, research consortia, public health institutions, and regulatory stakeholders to take part in upcoming seminars. To express interest or request participation, contact us at  engage@chelonia.swiss.


Stay tuned for more details on the next sessions by following our website and social channels.

About AVITHRAPID

AVITHRAPID is a European research initiative dedicated to accelerating antiviral drug discovery, leveraging advanced technologies and interdisciplinary collaboration to strengthen global health security against emerging viral threats.

Partners:

Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V., First Health Pharmaceuticals B.V., Instituto de Medicina Molecular Joao Lobo Antunes (iMM), Institut national de recherche pour l'agriculture, l'alimentation et l'environnement (INRAE), Università degli Studi della Tuscia (UNITUS), Università degli Studi di Siena (UNISI), Elettra Sincrotrone Trieste SCOA, Latvian Institute of Organic Synthesis (LIOS), Université de Tours (UT), University of Naples Federico II (UNINA), Swiss Tropical and Public Health Institute (Swiss TPH), Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani (INMI), Università degli Studi di Cagliari, Università degli Studi di Roma "Tor Vergata", Dompé Farmaceutici SpA, Euresist Network GEIE, IT4Innovations and Chelonia SA

 For more information, visit: www.avithrapid.eu

 Press Contact:

Ing. Silvano Coletti

CEO, CHELONIA SA

Chelonia SA | AVITHRAPID Communications

 silvano.coletti@chelonia.swiss